PK/PD Evaluation Resistance Development in Caseating Granuloma
干酪样肉芽肿的 PK/PD 评估耐药性发展
基本信息
- 批准号:7917381
- 负责人:
- 金额:$ 64.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-08-07 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvant TherapyAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAntibioticsAutopsyBacteriaCaviaClarithromycinDevelopmentDexamethasoneDoseDrug CombinationsDrug resistanceDrug usageEtanerceptEvaluationFiberFrequenciesGranulomaHigh Pressure Liquid ChromatographyImageImaging technologyImmunosuppressive AgentsIn SituIn VitroInflammationLabelLeadLesionLifeLungMicrobeModelingMusMycobacterium tuberculosisNecrosisOryctolagus cuniculusPathologicPatientsPenetrationPharmaceutical PreparationsPharmacodynamicsPhotonsPositronPositron-Emission TomographyPropertyRecombinantsRelative (related person)ResistanceResistance developmentRoleSamplingSerumSiteSteroidsSystemTestingThymidine KinaseTissuesTuberculosisX-Ray Computed Tomographybacterial resistancebasefialuridineinhibitor/antagonistnoveltooltuberculosis treatment
项目摘要
DESCRIPTION (provided by applicant): Active tuberculosis causes lung cavities where TB-bacteria grow to high levels. Cavitary TB is more transmissible to others, harder to treat in the patient who has it, and more likely to lead to drug resistance. This proposal will combine an animal model in which TB cavities reproducibly develop with novel radiologic imaging technologies and traditional pharmacologic tools to determine whether the TB cavity serves as a sanctuary site where bacteria may escape high drug concentrations and develop resistance. The last part of the study will determine whether giving immunosuppressive drugs which block cavity development together with antibiotics is useful in accelerating cure in an animal model of TB.
描述(由申请人提供):活动性结核病导致肺空洞,结核菌在肺空洞中生长到高水平。空洞性结核病更容易传染给他人,患者更难治疗,而且更有可能导致耐药性。该提议将联合收割机与新型放射成像技术和传统药理学工具结合,以确定结核腔是否作为细菌可能逃避高药物浓度并产生耐药性的避难所。这项研究的最后一部分将确定是否给予免疫抑制药物,阻止腔发展与抗生素一起是有用的,在加速治愈结核病的动物模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM Ramses BISHAI其他文献
WILLIAM Ramses BISHAI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM Ramses BISHAI', 18)}}的其他基金
Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV
介导结核病和结核病艾滋病毒性别差异的遗传和激素机制
- 批准号:
10557906 - 财政年份:2022
- 资助金额:
$ 64.6万 - 项目类别:
Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV
介导结核病和结核病艾滋病毒性别差异的遗传和激素机制
- 批准号:
10484064 - 财政年份:2022
- 资助金额:
$ 64.6万 - 项目类别:
Microbiology, Immunology, Animal Modeling and Imaging
微生物学、免疫学、动物建模和成像
- 批准号:
10431023 - 财政年份:2022
- 资助金额:
$ 64.6万 - 项目类别:
Microbiology, Immunology, Animal Modeling and Imaging
微生物学、免疫学、动物建模和成像
- 批准号:
10593152 - 财政年份:2022
- 资助金额:
$ 64.6万 - 项目类别:
Targeted cell-depleting immunotherapy for TB and HIV
结核病和艾滋病毒的靶向细胞消耗免疫疗法
- 批准号:
10556322 - 财政年份:2020
- 资助金额:
$ 64.6万 - 项目类别:
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
结核病和结核病艾滋病毒的谷氨酰胺代谢抑制剂:作为具有抗菌活性的宿主导向疗法的双重作用
- 批准号:
10686328 - 财政年份:2020
- 资助金额:
$ 64.6万 - 项目类别:
Targeted cell-depleting immunotherapy for TB and HIV
结核病和艾滋病毒的靶向细胞消耗免疫疗法
- 批准号:
10012368 - 财政年份:2020
- 资助金额:
$ 64.6万 - 项目类别:
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
结核病和结核病艾滋病毒的谷氨酰胺代谢抑制剂:具有抗菌活性的宿主导向疗法的双重作用
- 批准号:
10456845 - 财政年份:2020
- 资助金额:
$ 64.6万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 64.6万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 64.6万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 64.6万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 64.6万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 64.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 64.6万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 64.6万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 64.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 64.6万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 64.6万 - 项目类别:
Operating Grants